tetano
Editor, Senior Moderator
Aliment Pharmacol Ther. 2020 May 6. doi: 10.1111/apt.15814. [Epub ahead of print]
Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.
Garg M[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Royce SG[SUP]4[/SUP], Lubel JS[SUP]5[/SUP].
Author information
Abstract
We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].
This article is protected by copyright. All rights reserved.
PMID:32374032DOI:10.1111/apt.15814
Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.
Garg M[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Royce SG[SUP]4[/SUP], Lubel JS[SUP]5[/SUP].
Author information
Abstract
We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].
This article is protected by copyright. All rights reserved.
PMID:32374032DOI:10.1111/apt.15814